Cargando…
P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431077/ http://dx.doi.org/10.1097/01.HS9.0000971708.58435.e0 |
| _version_ | 1785091113972924416 |
|---|---|
| author | Wang, LI LI, Yuhua Zou, Dehui Zhu, Xiaojian Ji, Dongmei Qian, Wenbin Lu, Ying Ji, Chunyan Zhou, Keshu Jing, Hongmei Yang, Hua LI, Lanfang LI, Fei Xu, Kailin Niu, Ting Wu, Depei Hu, Yu Zhao, Wei-LI |
| author_facet | Wang, LI LI, Yuhua Zou, Dehui Zhu, Xiaojian Ji, Dongmei Qian, Wenbin Lu, Ying Ji, Chunyan Zhou, Keshu Jing, Hongmei Yang, Hua LI, Lanfang LI, Fei Xu, Kailin Niu, Ting Wu, Depei Hu, Yu Zhao, Wei-LI |
| author_sort | Wang, LI |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431077 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104310772023-08-17 P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION Wang, LI LI, Yuhua Zou, Dehui Zhu, Xiaojian Ji, Dongmei Qian, Wenbin Lu, Ying Ji, Chunyan Zhou, Keshu Jing, Hongmei Yang, Hua LI, Lanfang LI, Fei Xu, Kailin Niu, Ting Wu, Depei Hu, Yu Zhao, Wei-LI Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431077/ http://dx.doi.org/10.1097/01.HS9.0000971708.58435.e0 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Wang, LI LI, Yuhua Zou, Dehui Zhu, Xiaojian Ji, Dongmei Qian, Wenbin Lu, Ying Ji, Chunyan Zhou, Keshu Jing, Hongmei Yang, Hua LI, Lanfang LI, Fei Xu, Kailin Niu, Ting Wu, Depei Hu, Yu Zhao, Wei-LI P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION |
| title | P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION |
| title_full | P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION |
| title_fullStr | P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION |
| title_full_unstemmed | P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION |
| title_short | P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION |
| title_sort | p1203: efficacy and safety of axicabtagene ciloleucel (axi-cel) for the treatment of relapse/refractory non-hodgkin lymphoma: first real-world data in chinese population |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431077/ http://dx.doi.org/10.1097/01.HS9.0000971708.58435.e0 |
| work_keys_str_mv | AT wangli p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT liyuhua p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT zoudehui p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT zhuxiaojian p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT jidongmei p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT qianwenbin p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT luying p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT jichunyan p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT zhoukeshu p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT jinghongmei p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT yanghua p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT lilanfang p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT lifei p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT xukailin p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT niuting p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT wudepei p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT huyu p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation AT zhaoweili p1203efficacyandsafetyofaxicabtageneciloleucelaxicelforthetreatmentofrelapserefractorynonhodgkinlymphomafirstrealworlddatainchinesepopulation |